American International Group, Inc. Zentalis Pharmaceuticals, Inc. Transaction History

American International Group, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$10.83 - $16.49 $2,675 - $4,073	-247 Reduced 0.85%	28,701 $452,000
Q4 2023 Feb 13, 2024	SELL	$9.84 - $20.13 $1,151 - $2,355	-117 Reduced 0.4%	28,948 $438,000
Q3 2023 Nov 13, 2023	BUY	$19.63 - $28.29 $106,374 - $153,303	5,419 Added 22.92%	29,065 $583,000
Q2 2023 Aug 04, 2023	BUY	$17.41 - $30.05 $17,183 - $29,659	987 Added 4.36%	23,646 $667,000
Q1 2023 May 12, 2023	BUY	$16.14 - $24.94 $7,279 - $11,247	451 Added 2.03%	22,659 $389,000
Q4 2022 Feb 10, 2023	SELL	$18.07 - $25.6 $1,463 - $2,073	-81 Reduced 0.36%	22,208 $447,000
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $87,130 - $136,661	4,307 Added 23.95%	22,289 $483,000
Q2 2022 Aug 12, 2022	SELL	$17.91 - $52.25 $2,167 - $6,322	-121 Reduced 0.67%	17,982 $505,000
Q1 2022 May 13, 2022	SELL	$41.58 - $80.89 $53,056 - $103,215	-1,276 Reduced 6.58%	18,103 $835,000
Q4 2021 Feb 11, 2022	SELL	$66.92 - $84.79 $18,068 - $22,893	-270 Reduced 1.37%	19,379 $1.63 Million
Q3 2021 Nov 12, 2021	BUY	$46.83 - $73.5 $47,719 - $74,896	1,019 Added 5.47%	19,649 $1.31 Million
Q2 2021 Aug 13, 2021	BUY	$37.41 - $62.25 $70,143 - $116,718	1,875 Added 11.19%	18,630 $991,000
Q1 2021 May 07, 2021	BUY	$35.69 - $52.72 $1,570 - $2,319	44 Added 0.26%	16,755 $727,000
Q4 2020 Feb 12, 2021	BUY	$31.71 - $57.97 $311,360 - $569,207	9,819 Added 142.47%	16,711 $868,000
Q3 2020 Nov 04, 2020	BUY	$27.03 - $47.97 $15,380 - $27,294	569 Added 9.0%	6,892 $225,000
Q2 2020 Aug 12, 2020	BUY	$23.2 - $54.8 $146,693 - $346,500	6,323 New	6,323 $304,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.